Biodegradable Expandable Hemostatic Sponge Market Size, Share, Growth, and Industry Analysis, By Type (Surgical Hemostatic Sponge, Trauma Hemostatic Sponge, and Internal Hemostatic Sponge), By Downstream Industry (Hospital and Clinic), and Regional Forecast to 2033

Last Updated: 16 January 2025

BIODEGRADABLE EXPANDABLE HEMOSTATICS SPONGE MARKET OVERVIEW

The global biodegradable expandable hemostatic sponge market size was USD 4.2533 billion in 2024 and is projected to touch USD 8.8662 billion by 2033, exhibiting a CAGR of 8.5% during the forecast period.

Biodegradable expandable hemostatic sponge is a medical tool that has the distinctiveness of escalating when wet. This product is typically made from biocompatible substances for instance cellulose, collagen, and gelatin; these sponges endorse wound healing and quick blood clotting. They play a vital role in contemporary welling of health because it offers essential solutions for controlling bleeding during emergencies and surgical procedures. It is utilized for absorbing liquid and quickly stopping bleeding. They are essential in a variety of medical specialties due to their absorbent qualities and capacity to adapt to uneven wound surfaces.

The rising awareness worldwide and healthcare professionals’ growing comprehension of sophisticated treatments is opening avenues for producers to improve their products and increase their market grip. The growing elderly population and the growing occurrence of chronic illnesses that are employed for operational intervention are pushing the market intensification.

COVID-19 IMPACT

Biodegradable Expandable Hemostatic Sponge Industry Had a Negative Effect Due to supply chain disruption during COVID-19 Pandemic

The global COVID-19 pandemic has been unprecedented and staggering, with the market experiencing lower-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden market growth reflected by the rise in CAGR is attributable to the market’s growth and demand returning to pre-pandemic levels.

The COVID-19 pandemic has significantly affected the market expansion. The pandemic has resulted in supply chain disruption which has declined the availability of clotting products. The health management sector faced disruption because of the diversion of resources towards managing the pandemic. In addition, the postponement and cancelation of non-essential surgeries has obstructed the demand for the product. Conversely, the pandemic has increased and highlighted the importance of hemostats in managing bleeding complications coupled with the pandemic patients. Furthermore, as healthcare systems recover and operational procedures restart, the demand for the product is expected to rebound.

LATEST TREND

"Incorporation of Smart Technology to Drive Enhanced Market Growth"

A notable market trend is the combination of smart technologies such as wipes with implanted sensors for tracking and monitoring. These smart wipes can provide real-time data on wound conditions and enhance surgical outcomes. It is presenting an aggressive edge to manufacturers for producing modern products. In addition, the development of sponges with antimicrobial coating is gaining momentum, offering added protection against surgical-site infections and enhancing product value. A new technique that gives inventors a competitive edge is the use of 3D printing to create customized fibrinolysis sponges that are suited to particular surgeries demands is fueling the market growth.

BIODEGRADABLE EXPANDABLE HEMOSTATICS SPONGE MARKET SEGMENTATION

By Type

Based on Type, the global market can be categorized into surgical hemostatic sponge, trauma hemostatic sponge, and internal hemostatic sponge

• Surgical Hemostatic Sponge: These types of products are off-white and porous in appearance and it is a sterile, water-insoluble, supple, porcine gelatin absorbable wipe proposed for asepsis employed by applying to a bleeding surface.
• Trauma Hemostatic Sponge: It is a permeable material that can facilitate control bleeding in an injury by absorbing blood and trapping platelets and they are also important in emergency situations such as military strain and traffic accidents.
• Internal Hemostatic Sponge: It is a prescription device that can be used to control bleeding in non-compressible wounds before surgery and these products are used in a range of checkup procedures.

By Application

Based on application, the global market can be categorized into hospital and clinic

• Hospital: This segment is expected to dominate the market due to the high volume of medical procedures performed and the growing number of hospitals and the rising incidence of chronic diseases are also contributing to the market growth.
• Clinic: It includes specialized and general practice clinics, which are another important end-user segment for the product. These facilities often handle minor surgical procedures, wound care, and other cases that require effective bleeding control; the use of products in this segment is driven by their safety, ease of application, and ability to provide rapid coagulation. It also benefits from the reduced risk of complications and infections associated with biodegradable materials, making these agents a preferred choice for outpatient care.

MARKET DYNAMICS

Market dynamics include driving and restraining factors, opportunities and challenges stating the market conditions.  

Driving Factors

"Increased Operational Procedures and Demand for Hemostasis Products to Boost the Market"

The growing attribute for the biodegradable expandable hemostatic sponge market growth is the rise in the number of surgical procedures across various medical specialties is a significant aspect for the market growth. The further advancement in the field of healthcare creates large therapeutics gaps especially in patients that are consigned as problematic, resulting in an elected demand for improved clotting concentrates to treat bleeding and provide stabilization during surgery. It is confined to large surgical interventions as well as it ranges quite widely from elective surgeries to emergency procedures as well. The integration of recyclable clotting products is mainly valuable in health check settings, as they provide an effective solution for blood loss while reducing the risk of complications associated with non-biodegradable materials. In addition to surgeries, distressing injuries, accidents, and the increasing rate of chronic diseases also add to the demand for fibrinolysis products. As healthcare providers and institutions prioritize patient safety and optimal surgical outcomes, the need for effective thrombosis agents, particularly biodegradables options, becomes more pronounced.

"Rising Awareness of Sustainability and Eco-Friendly Products to Enlarge the Market Growth"

There is a growing global alertness regarding ecological issues and the change towards sustainability in medical practices. The market benefits from this trend, as biodegradable products are perceived as eco-friendly alternatives to traditional chemical-based hemostats. The ability of environment-friendly hemostats to minimize waste and their reduced environmental impact can enhance their appeal in various healthcare settings. This rising requirement for sustainable practices is driven by regulatory as well as by the inclinations of healthcare professionals and patients who favor environmentally responsible products. The market for biodegradable products is likely to expand as wellness program facilities strive to adopt greener practices, further boosting the growth of the market. Furthermore, the development of gelatin cleans with improved clotting properties, such as faster absorption rate and reduced risk of adverse reactions, enhances their appeal to health maintenance providers. These technological advancements improve patient outcomes as well as bolster the overall growth of the market by expanding the applications of the product across diverse surgical specialties.

Restraining Factor

"Stringent Regulatory for Product Approval to Potentially Impede Market Growth"

One of the most important limitations is the strict policies obligation for product approval is impeding the market growth. Organizational authorities compel rigorous standards for the safety, efficacy, and quality of asepsis agents, which can significantly prolong the time-to-market for new products and increase development costs for manufacturers that deter the purchasing power of end-users. Additionally, the availability of substitute clotting agents increases a market expansion threat to gelatin wipes. Synthetic polymers, oxidized regenerated cellulose, and other bio-absorbable hemostats offer comparable coagulation efficacy with potentially lower risks of allergic reactions and infections compared to gelatin based products. Healthcare providers may opt for these alternatives based on specific patient needs, clinical outcomes, and cost considerations, thereby affecting the market growth.

Opportunity

"Minimally invasive Surgical Techniques to Create Opportunity for the Market"

The promising opportunities are the increasing focus on minimally invasive surgical techniques. These techniques require precision tools and effective fibrinolysis to ensure successful outcomes. These products with their ability to provide rapid and efficient bleeding control are well-suited for use in minimally invasive procedures, the ongoing research and development activities aimed to enhancing the properties of clotting sponges to support minimally invasive surgeries are expected to create new avenues for the market expansion. Furthermore, with the development of advanced formulations that offer enhanced clotting properties and biocompatibility, manufacturers are investing in innovative technologies to create next-generation products capable of achieving faster coagulation, decreasing inflammatory responses, and endorsing superior wound healing outcomes.

Challenge

"Risk of Allergic Reactions and Complications Could Be a Potential Challenge for Market"

Adoption among specific patient groups and healthcare providers may be hindered by worries about negative reactions, such as allergies and infection brought on by specific sponge materials. In some countries, reimbursement for thrombosis agents may be limited and not available, which can reduce the demand for these products. Additionally, the high cost associated with biodegradable coagulation agents compared to traditional products. Additionally, the advanced resources and manufacturing processes complicated in producing ecological agents impel to their higher price point, which can be a hurdle to adoption, particularly in cost-sensitive healthcare settings.

BIODEGRADABLE EXPANDABLE HEMOSTATICS SPONGE MARKET REGIONAL INSIGHTS

• North America

North America is experiencing the highest biodegradable expandable hemostatic sponge market share because of its high pervasiveness of chronic diseases, increasing demand for advanced medical technologies, and well established health facility infrastructure. Furthermore, the increasing volume of various surgeries conducted in this region has fueled the product requirement which is further consolidating the region’s position as a prevailing force in the business. The United States biodegradable expandable hemostatic sponge market is the major market is highly developed and regulated, with stringent quality control and authoritarian frameworks in place. The existence of major medical device companies and research organizations has supported the market growth in this region. The famous participants in this region boast substantial expertise, resources, and well-established distribution networks are pushing market growth and subsequently increasing market share.

• Europe

Europe is anticipated to hold a considerable split of the market. The growing aspects are including a rising number of surgical procedures, increasing aging population, and an escalating healthcare spending. The adoption of advanced wound care solutions and regenerative medicine approaches is fueling the market growth. The major countries in this region are including the U.K., Germany, and France. The constant R&D activities in the region aimed at enhancing tools are impelling the market growth. In addition, the favorable compensation policies and government schemes to improve healthcare services encourage the market expansion in the region.

•  Asia

The Asia Pacific region is witnessing substantial growth in the market due to the increasing incidence of chronic diseases, increasing implementation of novel therapeutic technologies and improvement in healthcare infrastructure. The rapid modernization, growing populations, and strong demand from budding markets are thrusting market growth. In addition, the increasing knowledge regarding enhanced coagulate solution and rising medical tourism sectors in the region is also impelling demand for the products and consequently expanding the market growth.

KEY INDUSTRY PLAYERS

"Key Industry Players Shaping the Market through Product Development and Market Strategies"

The market is characterized by intense opposition, with numerous key players determined to maintain their market positions through wildly innovative and product development. The competitive background is marketed by tactical collaborations, mergers and acquisitions, and extensive research and development activities. Companies are paying attention to developing advanced coagulation solutions that offer superior efficacy, safety, and ease of use. Additionally, escalating their geographic existence and enhancing their distribution networks are crucial approaches adopted by market players to gain a competitive edge. The various corporations are actively engaged in research and development activities to introduce new and improved products. Their strong market presence, extensive product portfolios, and strategic initiatives fuel the viable dynamics of the market. The collective efforts of these players to improve and develop their market reach are expected to diversify the overall growth of the market.

LIST OF TOP BIODEGRADABLE EXPANDABLE HEMOSTATICS SPONGE COMPANIES

• Medtronic (Ireland)
• Johnson & Johnson (U.S.)
• Breath Medical (U.S.)
• Stryker Corporation (U.S.)
• Ethicon (U.S.)
• Baxter International (U.S.)

KEY INDUSTRY DEVELOPMENT

November 2023: Johnson & Johanson MedTech Company ‘Ethicon’ announced the approval of ETHIZIATM, an adjunctive hemostasis solution, which is clinically proven to achieve sustained hemostasis in difficult to control bleeding situations.

REPORT COVERAGE

The study encompasses a comprehensive SWOT analysis and provides insights into future developments within the market. It examines various factors that contribute to the growth of the market, exploring a wide range of market categories and potential applications that may impact its trajectory in the coming years. The analysis takes into account both current trends and historical turning points, providing a holistic understanding of the market's components and identifying potential areas for growth.

The biodegradable expandable hemostatic sponge market is poised for a continued boom pushed by rise in the number of surgical procedures across various medical specialties and growing worldwide awareness regarding environmental issues and the change towards sustainability in healthcare performs. Despite challenges, which include the high cost associated with ecological coagulation agents compared to traditional products and the tough regulatory requirements for product sanction. Major production players are robustly affiliated in exploration and progression actions to set up new and superior products. The well-built market companies have wide-ranging product portfolios, and deliberate initiatives to support the competitive spirit of the marketplace. The manufacturers are spending on innovative technologies to produce next-generation products that are expanding the market in the future. The increasing focus on the development of sophisticated formulations and desires for minimally invasive medical techniques that offer improved clotting functions and are tissue-friendly are bolstering market escalation.